Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16108848rdf:typepubmed:Citationlld:pubmed
pubmed-article:16108848lifeskim:mentionsumls-concept:C0332307lld:lifeskim
pubmed-article:16108848lifeskim:mentionsumls-concept:C0011860lld:lifeskim
pubmed-article:16108848lifeskim:mentionsumls-concept:C0038727lld:lifeskim
pubmed-article:16108848lifeskim:mentionsumls-concept:C0683149lld:lifeskim
pubmed-article:16108848lifeskim:mentionsumls-concept:C0332281lld:lifeskim
pubmed-article:16108848lifeskim:mentionsumls-concept:C0205251lld:lifeskim
pubmed-article:16108848lifeskim:mentionsumls-concept:C0150312lld:lifeskim
pubmed-article:16108848lifeskim:mentionsumls-concept:C1709701lld:lifeskim
pubmed-article:16108848pubmed:issue9lld:pubmed
pubmed-article:16108848pubmed:dateCreated2005-8-19lld:pubmed
pubmed-article:16108848pubmed:abstractTextThe glycosphingolipid sulfatide (sulfated galactosyl-ceramide) increases exocytosis of beta-cell secretory granules, activates K(ATP)-channels and is thereby able to influence insulin secretion through its presence in the islets. A closely related compound, sulfated lactosylceramide (sulf-lac-cer), is present in the islets during fetal and neonatal life when, as in Type 2 diabetes, insulin is secreted autonomically without the usual first phase response to glucose. The aim was to examine whether serum concentrations of these glycolipids are associated with Type 2 diabetes.lld:pubmed
pubmed-article:16108848pubmed:languageenglld:pubmed
pubmed-article:16108848pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16108848pubmed:citationSubsetIMlld:pubmed
pubmed-article:16108848pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16108848pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16108848pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16108848pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16108848pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16108848pubmed:statusMEDLINElld:pubmed
pubmed-article:16108848pubmed:monthSeplld:pubmed
pubmed-article:16108848pubmed:issn0742-3071lld:pubmed
pubmed-article:16108848pubmed:authorpubmed-author:BuschardKKlld:pubmed
pubmed-article:16108848pubmed:authorpubmed-author:HednerJJlld:pubmed
pubmed-article:16108848pubmed:authorpubmed-author:RåstamLLlld:pubmed
pubmed-article:16108848pubmed:authorpubmed-author:FredmanPPlld:pubmed
pubmed-article:16108848pubmed:authorpubmed-author:BlomqvistMMlld:pubmed
pubmed-article:16108848pubmed:authorpubmed-author:LindbladUUlld:pubmed
pubmed-article:16108848pubmed:authorpubmed-author:Bøg-HansenEElld:pubmed
pubmed-article:16108848pubmed:issnTypePrintlld:pubmed
pubmed-article:16108848pubmed:volume22lld:pubmed
pubmed-article:16108848pubmed:ownerNLMlld:pubmed
pubmed-article:16108848pubmed:authorsCompleteYlld:pubmed
pubmed-article:16108848pubmed:pagination1190-8lld:pubmed
pubmed-article:16108848pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:16108848pubmed:meshHeadingpubmed-meshheading:16108848...lld:pubmed
pubmed-article:16108848pubmed:meshHeadingpubmed-meshheading:16108848...lld:pubmed
pubmed-article:16108848pubmed:meshHeadingpubmed-meshheading:16108848...lld:pubmed
pubmed-article:16108848pubmed:meshHeadingpubmed-meshheading:16108848...lld:pubmed
pubmed-article:16108848pubmed:meshHeadingpubmed-meshheading:16108848...lld:pubmed
pubmed-article:16108848pubmed:meshHeadingpubmed-meshheading:16108848...lld:pubmed
pubmed-article:16108848pubmed:meshHeadingpubmed-meshheading:16108848...lld:pubmed
pubmed-article:16108848pubmed:meshHeadingpubmed-meshheading:16108848...lld:pubmed
pubmed-article:16108848pubmed:meshHeadingpubmed-meshheading:16108848...lld:pubmed
pubmed-article:16108848pubmed:meshHeadingpubmed-meshheading:16108848...lld:pubmed
pubmed-article:16108848pubmed:meshHeadingpubmed-meshheading:16108848...lld:pubmed
pubmed-article:16108848pubmed:meshHeadingpubmed-meshheading:16108848...lld:pubmed
pubmed-article:16108848pubmed:meshHeadingpubmed-meshheading:16108848...lld:pubmed
pubmed-article:16108848pubmed:meshHeadingpubmed-meshheading:16108848...lld:pubmed
pubmed-article:16108848pubmed:meshHeadingpubmed-meshheading:16108848...lld:pubmed
pubmed-article:16108848pubmed:year2005lld:pubmed
pubmed-article:16108848pubmed:articleTitleLow serum concentration of sulfatide and presence of sulfated lactosylceramid are associated with Type 2 diabetes. The Skaraborg Project.lld:pubmed
pubmed-article:16108848pubmed:affiliationBartholin Instituttet, Rigshospitalet, Copenhagen, Denmark.lld:pubmed
pubmed-article:16108848pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16108848pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16108848lld:pubmed